|Bid||23.61 x 3100|
|Ask||23.57 x 1800|
|Day's Range||21.09 - 25.79|
|52 Week Range||1.94 - 25.79|
|Beta (3Y Monthly)||3.96|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
On a per-share basis, the New York-based company said it had a loss of 32 cents. Axsome shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...
Axsome Therapeutics Inc. (AXSM) gained 39 cents to $19.54 on Tuesday on 1.4 million shares traded. The biotech company announced Monday that the FDA granted breakthrough therapy designation for a major depressive disorder treatment. It’s now right at lateral resistance, a break through which could lead to the $20 range short-term.
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The ...
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Axsome Therapeutics Inc (NASDAQ: AXSM) has been a standout performer among biotech stocks year-to-date. Axsome announced Monday that the FDA granted Breakthrough Therapy Designation for its AXS-05, which is being evaluated for major depressive disorder, or MDD, and treatment-resistant depression, or TRD. With the expedited development program, the company said its previously completed ASCEND Phase 2 trial is adequate to file an NDA for MDD.
Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).
Biotech funds have stalled at key retracement levels after strong first quarter bounces and could sell off in the coming weeks, but small biotech stocks are still glued to the top of market performance lists, hitting new highs while posting outsized returns. It's wise to keep one eye on the research calendar when trading small biotech stocks with compounds in the pipeline, hitting the sidelines ahead of key dates because these issues can drop 50% or more overnight after adverse results. New York-based Axsome Therapeutics, Inc. (AXSM) researches and develops compounds and therapies for Alzheimer's disease and other central nervous system disorders.
On CNBC's "Mad Money Lightning Round," Jim Cramer said SurveyMonkey (NASDAQ: SVMK ) had a fabulous quarter and it should have naver traded lower. Cramer has to do more research on Axsome Therapeutics ...
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 88.28% for Axsome Therapeutics (AXSM) based on the company’s closing
Axsome Therapeutics Inc. shares jumped 13% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder. The designation, given to the company's AXS-05 oral, investigational NMDA receptor antagonist, gives drug companies an expedited development and review timeline for drugs that are deemed to offer a significant improvement over existing therapies for a serious or life-threatening condition. The decision to award it was based on results from a mid-stage trial that showed a substantial reduction in depressive symptoms. Major depressive disorder affects about 6.7% of U.S. adults and is a chronic, biologically based disorder that can result in suicide. Axsome shares have gained a stunning 468% in the last 12 months, while the S&P 500 has gained 7.9%.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulatedRead More...